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Diagnosis of early-stage acute kidney injury (AKI) will benefit from a timely identification of local tissue hyp-
oxia. Renal tissue hypoxia is an early feature in AKI pathophysiology, and renal oxygenation is increasingly
being assessed through T2*-weighted magnetic resonance imaging (MRI). However, changes in renal blood
volume fraction (BVf) confound renal T2*. The aim of this study was to assess the feasibility of intravascular
contrast-enhanced MRI for monitoring renal BVf during physiological interventions that are concomitant with
variations in BVf and to explore the possibility of correcting renal T2* for BVf variations. A dose-dependent
study of the contrast agent ferumoxytol was performed in rats. BVf was monitored throughout short-term oc-
clusion of the renal vein, which is known to markedly change renal blood partial pressure of O2 and BVf.
BVf calculated from MRI measurements was used to estimate oxygen saturation of hemoglobin (SO2). BVf
and SO2 were benchmarked against cortical data derived from near-infrared spectroscopy. As estimated
from magnetic resonance parametric maps of T2 and T2*, BVf was shown to increase, whereas SO2 was
shown to decline during venous occlusion (VO). This observation could be quantitatively reproduced in test–
retest scenarios. Changes in BVf and SO2 were in good agreement with data obtained from near-infrared
spectroscopy. Our findings provide motivation to advance multiparametric MRI for studying AKIs, with the
ultimate goal of translating MRI-based renal BVf mapping into clinical practice en route noninvasive renal
magnetic resonance oximetry as a method of assessing AKI and progression to chronic damage.
INTRODUCTION
Kidney diseases are a global health burden with steadily increas-
ing incidence (1-4), leading to an estimated worldwide death
toll of 2 million per year from AKI (5-7). The currently available
methods of assessing risk and therapeutic options for AKI are
limited (5, 6, 8-10). Although a number of biochemical markers are
being evaluated for use in diagnosis, risk assessment, and prognosis
of AKI, there are currently no specific biomarkers that permit
point-of-care diagnosis for early-stage AKI (4, 11, 12). Transla-
tional approaches for the assessment of early-stage AKI and for the
study of renoprotective strategies are urgently required (13-16).
Strategies under consideration include novel imaging techniques
that may be customized to probe early stages of AKI (12, 16-18).
Early features in the pathophysiology of AKI that could lend
themselves to detection by noninvasive magnetic resonance
(MR) imaging include renal tissue hypoperfusion and hypoxia—
factors that are also important during the progression from AKI to
chronic kidney diseases (16, 19-25). An imbalance between renal
oxygen supply and demand appears to also play a prominent role
in the pathophysiology of diabetic nephropathy (26). Renal oxy-
genation can be indirectly assessed through the blood oxygenation
level-dependent (BOLD) magnetic resonance imaging (MRI) con-
trast (27), which can be observed through measurements of effec-
tive transversal relaxation time T2*. Indeed, mapping of renal T2* (or
its reciprocal, R2*  1/T2*) is an established MRI method that is
increasingly being used to study kidney disorders (28-30).
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Renal BOLD MRI is based upon the T2* dependence on O2
saturation of hemoglobin (SO2) and motivated by the link be-
tween SO2, blood partial pressure of O2 (pO2), and tissue pO2.
However, questions have been raised regarding the interpreta-
tion of BOLD MRI data in the kidney as a surrogate of tissue
oxygenation (30). These concerns were triggered by the follow-
ing recent findings from renal T2* mapping: simultaneous renal
pO2 and T2* measurements showed considerable discrepancies in
the quantitative relationship between changes in renal T2* and
those in renal tissue pO2 for different functional regions of the
kidney and for various (patho)physiological scenarios (31). The
renal T2* to tissue pO2 relationship is not governed exclusively by
renal blood oxygenation, but it is also heavily influenced by a
number of confounders (30, 31). Of particular importance are
changes in the renal blood volume fraction (BVf). Renal T2*
reflects the amount of deoxygenated hemoglobin per tissue
volume, and any variation in BVf compromises the interpreta-
tion of T2* changes as reflecting alterations in blood oxygen-
ation, or even tissue oxygenation. This essential role of renal
BVf has been largely unheeded, although it was recently high-
lighted by reports on changes in renal vascular conductance,
local hemoglobin concentrations, and kidney size induced by
physiological interventions (31, 32). The impact of renal BVf
changes on T2* exceeds that of other organs’ BVf owing to the
considerably large BVf in the kidney (33). For these reasons, T2*
mapping alone cannot provide an unambiguous assessment of
renal oxygenation.
A comprehensive renal MR oximetry protocol could have a
quantitative value for the characterization of renal hemody-
namics and tissue oxygenation if it integrates an assessment of
renal BVf (30). Dynamic contrast-enhanced methods combined
with tracer kinetic principles allow the quantification of renal
perfusion and blood volume (34, 35) by using a bolus injection
of exogenous agents like gadolinium chelates or iron oxide
nanoparticles (36, 37). Analyzing the dynamic susceptibility
contrast changes during bolus passage necessitates fast imaging
with a temporal resolution of about 1 s, as well as measurement
of the arterial concentration–time curve and its deconvolution
from the tissue time curves. Renal dynamic susceptibility con-
trast was successfully implemented in dogs (36) and rats (37),
but the methodological requirements limit the achievable spatial
resolution and make this approach particularly challenging in
small animals.
More recently, steady-state renal BVf measurements were
performed by taking advantage of blood pool markers such as
ultrasmall superparamagnetic iron oxide (USPIO) agents (38, 39);
the change in transverse relaxation rate R2 was examined in the
kidney of mice (40) and rats (38). The steady-state approach
comprises the simple subtraction of pre- and postcontrast maps
of R2* (41) (or R2 if only small vessels are of interest), and it has
the further benefit of facilitating the continuous monitoring of
renal BVf (38). The USPIO nanoparticle preparation ferumoxytol
has proven very useful for this (38, 42-45), as it can be administered
intravenously without the risk of impaired renal oxygenation or
perfusion (46), and it exhibits a long intravascular half-life of
14 h in humans and 2 h in small rodents (43, 44, 47).
The goal of the current study was to determine whether
intravascular contrast-enhanced MRI can be used as a means of
monitoring BVf in physiological settings, in which significant
variations in both renal BVf and renal oxygenation are expected,
and, furthermore, to explore the possibility of correcting renal
BOLDmeasurements for BVf variations. A previous study by Storey
et al. (38) used steady-state BVf monitoring during the administra-
tion of vasoactive drugs, but the induced R2 variations (in the
absence of USPIO) were attributed to changes in tubular volume
fraction rather than BVf or oxygenation. Here, we investigate the
feasibility of renal BVf monitoring in rat kidneys at 9.4 T as a
means of achieving a comprehensive renal MR oximetry protocol.
For this purpose, ferumoxytol-enhanced renal T2* and T2 mappings
were performed under baseline conditions and after a short-term
reversible intervention of renal vein occlusion. This intervention is
known to cause marked changes in renal blood pO2 and renal BVf.
Local BVf was calculated on the basis of changes in T2*, which is
equally sensitive to vessels of all sizes, unlike previous works
that used T2 (38, 40), which is more sensitive to small vessels
(48). Local SO2 of the kidney was estimated using a model-based
multiparametric MR technique (49), and variations in BVf and
SO2 were benchmarked against reference data obtained from
near-infrared spectroscopy (NIRS). Given the lack of informa-
tion in the literature on a suitable ferumoxytol dose for renal
BVf measurements at 9.4 T, we performed dosage experiments to
establish a useful level of sensitivity to changes in BVf and SO2.
METHODOLOGY
Animal Preparation and Control of Vital Functions
All experiments were approved by the Animal Welfare Depart-
ment of the Berlin State Office of Health and Social Affairs and
were performed in accordance with the German Animal Protection
Law. The procuration of animals, husbandry, and experiments
conformed to the European Convention for the Protection of
Vertebrate Animals used for Experimental and Other Scientific
Purposes (Council of Europe No 123, Strasbourg 1985). Male
Wistar rats (age, 12–13 weeks; body weight [BW], 288–330 g;
n  4; Harlan-Winkelmann, Borchen, Germany) underwent
surgical preparation and MRI under urethane anesthesia (20% in
H2O; 6 mL/kg BW intraperitoneal; Sigma-Aldrich, Steinheim,
Germany). In this approach, anesthesia is provided for several
hours, leaving cardiovascular reflexes largely undisturbed.
To monitor arterial blood pressure, a catheter was placed
into the femoral artery with its tip pointing towards the aorta.
The catheter was connected to a pressure transducer (DT-XX,
Viggo-Spectramed, Swindon, UK) and an amplifier (TAM-A
Plugsys Transducer; Hugo Sachs Elektronik—Harvard Apparatus
GmbH, March-Hugstetten, Germany). A second catheter was
inserted into the right jugular vein, which permitted the admin-
istration of isotonic saline and USPIO. Core body temperature
was monitored within the abdominal cavity by means of a
fiber-optic temperature probe (OTP-M, AccuSens, Opsens, Québec
City, Canada). Body temperaturewasmaintained at 37°Cwith a pad
supplied with steady warm water circulation.
Renal VO as Test Intervention
To induce renal VO during the MR study, a remotely operated
inflatable cuff (occluder) was positioned around the left renal
vein. Time-of-flight (TOF)-based MR angiography was performed
immediately after cuff inflation and deflation to confirm the suc-
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cessful occlusion and reperfusion of the kidney. In the rare case of
a failed occlusion, we could detect the problem quickly and could
perform a second attempt of the stimulus without a substantial
delay.
The occlusion of the renal vein is known to induce both
deoxygenation of the intrarenal blood and a substantial increase
in intrarenal blood volume (32). Cessation of the venous outflow
of blood increases blood pressure in intrarenal veins, thus resulting
in their circular distension. The increased amount of deoxygenated
blood in the renal tissue amplifies the BOLD effect, which induces
a reduction in the T2*-weighted MR signal in response to VO. A
further reduction in the MR signal due to T2* shortening induced
by the USPIO might lower the signal-to-noise ratio (SNR) to a
critical level at which the MR image/data quality might become
insufficient. Therefore, VO in combination with USPIO repre-
sents an extreme scenario with respect to the expected T2* short-
ening.
BVf Measurement
BVf was measured using the USPIO ferumoxytol (Feraheme®,
AMAG Pharmaceuticals, Inc., Lexington, MA). Ferumoxytol is
approved in the USA and the EU as an intravascular Fe supple-
ment therapy for patients with iron deficiency anemia related to
chronic kidney disease. The intravenous injection of ferumoxy-
tol does not have any measurable effects on renal physiology at
doses up to 41 mg Fe/kg BW in rats; the presence of ferumoxytol
also does not significantly alter the control of renal hemody-
namics and oxygenation as studied by aortic occlusion and
hypoxia (46).
Renal BVf was calculated by comparing pre-ferumoxytol
data (R2*-maps) with post-ferumoxytol data (R2*USPIO-maps)
(41):
BVf
3
4
·
(R*2,USPIO  R*2 )
USPIO · B0 · 

3
4
·
R*2,USPIO
USPIO · B0 · 
(1)
where  is the gyromagnetic ratio, which is 2.675  108 rad/(s T);
B0  9.4 T; and USPIO is the susceptibility difference between
blood with and without added USPIO:USPIO 0.024 ppm (cgs
units)  [USPIO dose in milligram Fe per kilogram BW] (50).
Ferumoxytol Dose-Finding Study
Considering the lack of information on a suitable ferumoxytol
dose for renal BVf measurements at 9.4 T, we performed a
dose-finding study. To accomplish this, the following 3 compet-
ing effects had to be balanced:
Figure 1. Illustration of experi-
mental protocol. Magnetic reso-
nance (MR) monitoring of a base-
line–stimulus–recovery cycle was
performed 5 times: once without
ultrasmall superparamagnetic iron
oxide (USPIO) (phase 1) and 4
successive times (phases 2–5)
each with an incremental dose of
USPIO.
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(1) sensitivity of the BVf measurements increases with the
USPIO dose;
(2) the SNR of MR images decreases with the USPIO dose; and
(3) sensitivity to changes in BVf also decreases at high USPIO
doses because T2* tends to zero.
For these reasons, a ferumoxytol dose ranging from 2 to
8 mg Fe/kg BW was used.
Experimental Protocol
The experimental protocol comprised 5 phases with increasing
cumulative doses of ferumoxytol as illustrated in Figure 1:
(1) Phase 1: Baseline–stimulus–recovery without USPIO
(a) Baseline T2* and T2 mapping and TOF MR angiographic
confirmation of renal blood flow.
(b) VO performed by remote inflation of the cuff.
(c) The absence of renal blood flow was checked immedi-
ately using TOF MR angiography.
(d) T2* and T2 mapping during VO.
(e) Release of the venous cuff. Effective duration of
VO was 3 min (depended on acquisition time of
respiration-gated MRI scans performed in steps c
and d).
(f) Restoration of renal blood flow was checked by TOF
angiography
(g) Recovery phase, during which T2* and T2 mapping was
continued: 5 repetitions, approximately every 3 mins
covering a 12- to 14-min period (dependent of respira-
tory rate because scans were respiration-triggered)
(2) Phase 2: Baseline–stimulus–recovery with first USPIO
dose
(h) The intravascular contrast agent (USPIO; 2 mg of
Fe/kg body mass) was administered using a power
injector at a rate of 0.25 mL/min via the jugular vein
catheter.
(i—o) Following the conclusion of the injection and an
additional 3-min mixing time, the steps of phase 1
were repeated to obtain matching post-USPIO data
for phase 1.
(3) Phase 3: Baseline–stimulus–recovery with second USPIO
dose
Same as phase 2 but with a different USPIO dose: the addi-
tional injection of 2 mg of Fe/kg USPIO yielded the approximate
cumulative dose of 4 mg of Fe/kg USPIO (owing to the long
half-live of the USPIO).
(4) Phase 4: Baseline–stimulus–recovery with third USPIO
dose
Same as phase 2 but with a different USPIO dose; the
additional injection of 2 mg of Fe/kg USPIO yielded an approx-
imate cumulative dose of 6 mg of Fe/kg USPIO.
(5) Phase 5: Baseline–stimulus–recovery with fourth USPIO
dose
Same as phase 2 but with a different USPIO dose; the
additional injection of 2 mg of Fe/kg USPIO yielded the approx-
imate cumulative dose of 8 mg of Fe/kg USPIO.
The duration of the experimental phase was 20 min,
which is short in comparison to the duration of the plasma
half-life of ferumoxytol in rats (up to 3 h) (38).
MR Imaging Experiments
MRI experiments were performed on a 9.4 T animal MR system
(Biospec 94/20, Bruker Biospin, Ettlingen, Germany) using a
radiofrequency (RF) coil setup established for renal imaging
(linear polarized birdcage RF resonator for transmission in con-
junction with a curved 4-channel receive RF coil array; Bruker
Biospin, Ettlingen, Germany).
T2-weighted pilot scans for geometrical planning and sec-
tion positioning were acquired. We conducted a local volume-
selective shimming of the magnetic field homogeneity on a
voxel enclosing only the kidney, using an automatic optimiza-
tion algorithm based on the FID length.
Interleaved T2* and T2 mapping was performed with respi-
ratory-gated (Model 1025, SA Instruments, Stony Brook, NY)
imaging protocols. For T2* mapping, a multiecho gradient-echo
Figure 2. Semiautomated kidney segmentation.
A region-of-interest (ROI) analysis was performed
to obtain representative mean values for each re-
nal layer. Guided by a manually drawn reference
frame and tangents, 10 ROIs were placed auto-
matically at locations in the cortex and outer me-
dulla. The ROI locations were chosen on the basis
of measurements taken on excised kidneys and
histological sections of Wistar rat kidneys. ROI
positions are given in percentages of the refer-
ence frame and diagonals.
TOMOGRAPHY.ORG | VOLUME 3 NUMBER 4 | DECEMBER 2017 191
(MGE) sequence (repetition time [TR] 50 milliseconds; number
of echoes 10; first echo time [TE] 1.43 milliseconds; TE
2.14 milliseconds; averages  4) with a total acquisition time
of 1 min 20 s was used. For T2 mapping, a multi-spin echo
(MSME) sequence (TR 550 milliseconds; number of echoes 7;
first TE  10 milliseconds; TE  10 milliseconds; averages  1)
with a total acquisition time of around 1 min 40 s was applied.
For MGE measurements, the respiratory trigger window in-
cluded the entire expiratory plateau, which allowed for the
acquisition of several k-space lines within this window. For
MSME measurements, the respiratory trigger window was set to
10 milliseconds at the beginning of the expiratory plateau,
resulting in the acquisition of 1 k-space line per breath, with the
effective TR being equal to the respiratory interval.
A coronal oblique section was placed such that it covered
the kidney centrally at its maximum extension. An in-plane
spatial resolution of (226  445) m2, field of view  (38.2 
50.3) mm2, matrix size  169  113 zero-filled to 169  215,
and a section thickness of 1.4–1.5 mm was used.
For TOF angiography, we used a spoiled gradient echo
technique (2D FLASH; TR  11 milliseconds; TE  3 millisec-
onds; flip angle 80°) with a spatial in-plane resolution of (200
268) m2 and 15 sections (section thickness  1.0 mm).
Region of Interest Analysis
We extended the semiautomated kidney segmentation approach
used in our previous studies (31, 51) to provide 5 regions of
interest (ROIs) in the renal cortex and 5 ROIs in the renal outer
medulla (Figure 2). In brief, a rectangle was manually placed
around the kidney borders, followed by drawing lines at the
crossing of the kidney border and 2 automatically placed diag-
onals. Further, 10 ROIs were placed automatically at locations in
the cortex and outer medulla that had been predefined with
respect to the reference rectangle.
Effects of Magnetic Field Inhomogeneity on Renal T2*
Three-dimensional mapping of B0 was performed to correct the
B0 inhomogeneity effects on T2* (49). This B0 correction involves
(i) acquiring a 3D B0 map of the kidney; (ii) estimating intra-voxel
field dispersion across the kidney by fitting a 3D polynomial to the
B0 map; (iii) calculating intravoxel dephasing; and (iv) using this
for correcting the measured T2* map of the kidney.
To assess the need for B0 correction in renal T2* mapping, we
performed B0 correction on a kidney for different shim settings and
compared the corrected renal T2*-maps with the measured, uncor-
rected T2*-maps. All shims were first set to zero to allow for signif-
icant B0 inhomogeneities, and then first-order local shimming
was performed on a voxel tightly enclosing the kidney to make
B0 uniform across the kidney. The latter was performed 3 times
to account for any variability. A 3D polynomial function of the
third order was fitted to the measured 3D B0 map (in-house
developed program; MATLAB, MathWorks, Natick, WA). This
polynomial function was used to estimate the spin dephasing on
a subvoxel grid of 2 2 4 voxels per image voxel (voxel size
0.22  0.23  1.40 mm3). Subvoxel grids finer than 2  2  4
did not yield significantly different results.
Model-Based MRI Data Analysis
Multiecho MR data were converted into parametric maps of
absolute T2* and T2 by pixelwise monoexponential fitting to
the signal intensities of denoised (SANLM filter, VBM8 toolbox,
SPM8; www.fil.ion.ucl.ac.uk/spm) series of T2*- and T2-weighted im-
ages acquired as a function of the TE (in-house developed
program; MATLAB, MathWorks, Natick, WA). The relaxation
rates were calculated as R2*  1/T2* and R2  1/T2. The subtrac-
tion of precontrast maps from corresponding postcontrast maps
yielded R2*-maps, which were used for the calculation of BVf-
maps using equation (1).
Figure 3. Left: Monte Carlo simulations were used to estimate the error in the fitted T2* versus the true T2* for a wide
range of signal-to-noise ratios (SNRs). Each color-coded “pixel” in the matrix represents a simulated combination of true
T2* (1–50 milliseconds) and SNR (10 to 1000). The color indicates the mean absolute error in 10 000 T2* fit simula-
tions. Right: Overlaid boxes outline the typical ranges of T2* and SNR measured in vivo at different Fe doses. In vivo, the
cortical and outer medullary T2* error is 1 millisecond.
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Renal blood SO2 was estimated by applying a multipara-
metric MR technique (49) to the R2*, R2 and BVf data from the
kidney. This approach was originally proposed for human brain
MRI (52) and is based on a theoretical model of the BOLD
contrast (53). This approach was refined by replacing a complex
model fit with a simpler single parameter fit combined with
actual MR measurements of R2, BVf, and B0 (49). Assuming that
the magnetic field inhomogeneity is negligible and constant
throughout the duration of the experiment, we solved the model
equation s(t)  f (t, BVf, SO2, . . .) for SO2  f (R2*, R2, BVf, . . .):
SO2  1  34 · (R*2  R2) · 0 · BVf · Hct · B0 (2)
Here 0  0.264 ppm (54), which represents the suscepti-
bility difference between deoxygenated and oxygenated red
blood cells, B0  9.4 T, and SO2 is given in arbitrary units
(because B0 is uncorrected). A hematocrit of 0.40 was used for
the cortex and the outer medulla (85%–95% of systemic hemat-
ocrit, which was assumed to be 0.45) (55). In this feasibility
study, the data analysis was performed using equations (1) and
(2), as these permit access to both parameters of interest, that is,
SO2 and BVf.
To evaluate intrasubject reproducibility, we compared results
from the baseline with those obtained after 10 min of recovery and
also repeated the baseline–occlusion–recovery experiment (25
min later). Moreover, before repeating the experiment, we in-
creased theUSPIO dose by 2mgFe/kg BW to assess the dependency
of the results on the USPIO dose.
NIRS
Quantitative information on the relative changes of total corti-
cal hemoglobin per tissue volume (as a surrogate for BVf) and
cortical SO2 during VO were obtained using multidistance con-
tinuous wave NIRS in a separate cohort of 10 male Wistar rats.
The NIRS measurements are based on recording spatially re-
solved diffuse reflectance with a linear fiber probe. This probe
permitted sampling of the renal tissue up to a maximum depth of
2 mm and provided information about the renal cortex. The
results presented here were obtained by a refined model analysis
of data reported in Grosenick et al. (32), with improved separation
of tissue absorption changes from changes in tissue scattering. To
reference our results against these data, the high-temporal-resolu-
tion NIRS data were averaged over the duration of each MGE MRI
scan.
Figure 4. T2*-weighted images
(echo time [TE]  3.6 millisec-
onds, spatial resolution  226 
422 m) of a rat kidney at base-
line, during venous occlusion
(VO), and at the beginning of the
recovery phase. Without USPIO
(top row), the short-term VO in-
duces a very strong signal de-
crease in the renal cortex and the
outer medulla. The impact of
USPIO administration on T2*-
weighted image contrast (left col-
umn) lends itself to an estimation
of blood volume fraction (BVf). A
hypointense area stretching from
the papilla via the inner medulla
to the central outer medulla be-
comes prominent with increasing
USPIO dose. This hypointensity
might represent the influence of
large Fe-rich vessels located close
to the image section rather than
medullary tissue properties (see
Discussion).
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RESULTS
Ferumoxytol Dose-Finding Study
The dose-finding study was performed to ensure that BOLD
effects were detectable after USPIO administration taking into
account that SNR may be further reduced by changes in T2*
owing to the deoxygenation of blood. By performing Monte
Carlo simulations for a wide range of T2* and SNR, we estimated
the SNR-dependence of the T2* mapping error (Figure 3).
T*2,error T*2,calcT*2,true (3)
with “true” indicating the true T2* value used as an input and
“calc” indicating the T2* value calculated by curve fitting to the
noisy signal intensity data versus TE. For cortical and outer
medullary T2* the absolute error in T2* was 1.0 milliseconds.
T2*-Weighted MR Imaging
We observed a significant change in contrast and image quality
following short-term VO and after increasing USPIO concentra-
tions (Figure 4). VO caused a very strong signal decrease in the
renal cortex and in the outer medulla. Even after a USPIO
administration of 4 or 6 mg of Fe/kg BW, the strength of this
decrease of the signal during VO remained similar and was
easily detectable. Although the signal loss suggested renal hyp-
oxia, that is, a decrease in oxygen saturation of hemoglobin, this
remained speculative because, at this point, possible changes in
BVf had not been considered. Comparing the T2*-weighted im-
ages at baselines for different USPIO doses shows the impact of
USPIO administration on image contrast, which lends itself to an
estimation of BVf.
Important for estimating the BVf is the sensitivity for de-
tecting the change in T2* caused by labeling the blood with
USPIO. As expected, a larger USPIO dose provided more sensi-
tivity for the measurement of:
T*2,USPIO T*2,USPIOT*2 (4)
because the larger the cumulative USPIO dose, the larger the
change in T2* compared with the baseline (Figure 5A). This T2*
change was more pronounced in the outer medulla than in the
renal cortex. In contrast to the sensitivity to USPIO effects, the
sensitivity to changes in T2* induced by VO decreased rapidly
with the Fe dose (Figure 5B):
T*2,VO T*2,VOT*2,baseline (5)
The sensitivity to changes in T2* induced by VO fell below
T2*  2.0 milliseconds in the outer medulla for USPIO doses of
6 mg of Fe/kg and more. The relative T2*, as percentage of
baseline T2*, did not change much and stayed between 60%
and 80%.
Considering the sensitivity of T2* to USPIO injection (rele-
vant for BVf estimation) and the T2* sensitivity to the physiolog-
ical stimulus, that is, VO, a USPIO dose of 4 mg of Fe/kg BW was
chosen for estimating R2* and ultimately for the BVf- and SO2-
maps.
Effects of Magnetic Field Inhomogeneity on Renal T2*
Macroscopic gradients in the magnetic field B0—for instance,
owing to imperfect B0 shimming—may cause undesirable spin
dephasing and could artificially shorten T2*. Before mapping
renal R2*, BVf, and SO2, we tested whether the susceptibility
weighting and T2* were dominated by microscopic B0 suscepti-
bility gradients. We investigated whether B0 correction could
reverse unwanted magnetic field inhomogeneity effects on T2* by
comparing measured and corrected renal T2*-maps acquired in
vivo for different magnetic field shim settings as shown in
Figure 6.
The 3D polynomial fits to the measured B0-maps described
the magnetic field inhomogeneity with high fidelity. A notable
Figure 5. Comparison of the T2* sensitivity to
USPIO injection (relevant for BVf estimation) and
the T2* sensitivity to VO (physiological stimulus) at
different cumulative USPIO doses. Plots of
changes in cortical and outer medullary T2* in-
duced by the injections of USPIO (A). Absolute
T2* in milliseconds (left panel) and relative T2*
as percentage of T2* without USPIO (right panel)
increased rapidly with USPIO dose. Plots of
changes in cortical and outer medullary T2* in-
duced by VO (T2* values during a given VO ver-
sus T2* before the respective VO) (A). Although
absolute T2* in milliseconds (left panel) de-
creased with USPIO dose, the percentage T2*
(right panel) remained between 60% and 80%.
Group means and SEMs (n  4) of cortical and
outer medullary T2* obtained from the ROIs are
determined as shown in Figure 2.
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macroscopic magnetic field inhomogeneity was present with the
shim settings adjusted to zero. For this shim setting, B0 correc-
tion markedly increased T2*, particularly in the inner medulla,
where T2* is typically large. B0 inhomogeneity across the kidney
was very small after local shimming on the kidney. After B0
correction, the renal T2*-maps obtained for all 3 B0 shim settings
displayed high agreement. For local shimming, which we per-
form routinely in renal MR studies, the effect of B0 correction on
T2* was negligible. This confirms that macroscopic intravoxel
dephasing causes only minor T2* effects for the TE range and the
voxel size used and ensures that T2* is governed by microscopic
B0 susceptibility gradients.
Renal R2*, R2, BVf, and SO2 Mapping
Parametric maps were calculated for renal T2 and T2*, which were
then converted to R2- and R2*-maps, respectively. Such quanti-
tative maps permit comparisons between animals and over time,
as they are not biased by external factors such as RF coil
sensitivity (B1) or the position of the subject under investi-
gation with respect to the receive RF coil. The difference
between R2*- and R2-maps (R2* and R2, respectively), acquired
before and after USPIO administration is closely related to the
local BVf. The blood volume measurement procedure is illus-
trated in Figure 7, which shows parametric maps of renal R2 and
R2* relaxation rates under baseline conditions, without and with
USPIO (4 mg of Fe/kg), along with their difference. Dissimilari-
ties between R2* and R2 are expected owing to their different
sensitivities to large vessels (see Discussion).
Analysis of BVf-maps obtained at baseline and during
renal VO (Figure 8) revealed an increase in cortical and
medullary BVf upon VO. Renal BVf returned to baseline after
10 min of recovery. Next, maps of renal SO2 were calculated
using the multiparametric BOLD model outlined in equation
(2), which requires T2* and BVf as input data to analyze SO2 at
baseline, upon VO and on recovery (Figure 8). The reduction
in renal T2* during VO was associated with a decrease in SO2 in the
cortex and outer medulla combined with a substantial increase in
blood volume.
To show the necessity of monitoring BVf (rather than using
a fixed literature value), we also calculated SO2-maps that as-
sume renal BVf to remain constant and identical to the baseline
condition during the entire experiment (Figure 8, lower panel).
Almost everywhere in the cortex and outer medulla, SO2 values
were considerably lower in the experiments neglecting BVf
changes compared with experiments taking BVf changes into
account.
Reproducibility of results was very high: the results ob-
tained for the cortical and outer medullary BVf and SO2 at
baseline conditions and after 10 min of recovery were almost
Figure 6. B0 correction for re-
moving macroscopic magnetic
field inhomogeneity effects on
T2*. Fitting a 3D polynomial func-
tion to the measured B0 map per-
mits calculation of the intravoxel
magnetic field distribution. The
spin dephasing caused by un-
wanted macroscopic gradients
can then be calculated and used
to correct the measured T2*. The
parameter maps illustrate the B0
correction performed for T2* map-
ping of a rat kidney in vivo. Four
different shim settings were used:
all shims set to 0 (top row) and a
first-order local shim on a voxel
tightly enclosing the kidney,
which was performed 3 times
(rows 2–4) to assess variability.
In the absence of shimming, the
difference between the measured
and corrected T2*-maps was nota-
ble. In contrast, the difference
between measured and corrected
T2*-maps was only minor when
local shimming on the kidney had
been performed.
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indistinguishable (Figure 8). This finding is strengthened by the
test–retest reliability (with 4 and 6 mg of Fe/kg BW USPIO):
differences between both iterations were practically negligible,
despite the fact that USPIO had been injected in between them.
This result confirmed that the BVf calculation appropriately
accounted for the effect of the USPIO dose. In the parameter
maps, the inner medulla is not shown, as no justifiable assump-
tions about the hematocrit and liquid fraction in this region
could be made. In our study, as well as in previous reports, the
inner medullary R2 was much higher than cortex and outer
medulla R2, suggesting high water content. This result disagrees
with observations in human kidneys and conceivably might be
because of the inclusion of partial volumes of the adjacent renal
pelvis in the image section.
Qualitative Comparison With NIRS
The estimates of occlusion-induced changes in renal BVf and
SO2 obtained from MRI were benchmarked against quantitative
parameters obtained for the renal cortex by means of NIRS. The
relative changes (from baseline to VO) in cortical total hemo-
globin concentration and SO2 measured by NIRS were compared
with the relative changes in cortical BVf and SO2 derived from
an ROI analysis on the MR parameter maps (Figure 9).
The MR data and NIRS data showed good agreement: cor-
tical SO2 decreased markedly during the short-term VO for both
methods. The nearly 2-fold increase in cortical BVf measured
with MRI during VO was mirrored by a similar increase in hemo-
globin tissue concentration, as measured by NIRS. As for the
injected USPIO, hemoglobin effectively serves as a naturally
occurring label in the blood, and hence, its tissue concentration
may be regarded as a surrogate for BVf, as long as the hemat-
ocrit remains unchanged.
DISCUSSION
This work makes an important contribution to the literature
on renal functional MRI by assessing changes in the renal BVf
and in the renal SO2 in response to VO. To achieve this goal, BVf
measurements were implemented for rat kidneys at 9.4 T, in-
cluding a dose-finding study for the intravascular contrast
agent ferumoxytol. Multiparametric analysis was performed to
estimate renal SO2. Occlusion-induced changes in BVf and SO2
derived from MRI were benchmarked against BVf and SO2 ref-
erences obtained from NIRS. Our main findings are that (1) a 4
mg of Fe/kg dose of ferumoxytol is suitable for BVf measure-
ments at 9.4 T using baseline, VO and recovery; (2) the proposed
approach provides high reproducibility for BVf and SO2 assess-
ment as demonstrated by the test–retest experiments; (3) relative
changes in cortical BVf and cortical SO2 derived from MRI were
in accordance with relative changes in BVf and SO2 deduced
from NIRS; and (4) without the monitoring of BVf, MRI overes-
timates the SO2 decrease during renal VO. The results of this
work permitted a noninvasive detection of BVf increase upon
VO and a removal of its effects on blood oxygenation-sensitized
renal MR.
We found BVf to be higher in both outer and inner medulla
than in the cortex, as shown by both R2- and R2*-maps.
Although these observations do not agree with recent results
obtained by 3D microcomputed tomography (where cortical BVf
was reported to be larger than medullary BVf) (56), they are in
alignment with previous reports on R2-based BVf estimates in
rats and mice (38, 40), as well as with a series of earlier reports
that measured renal BVf by means of (51) Cr-labelled red cells
and 125I-M-immunoglobulin: Rasmussen (55) reported medul-
lary BVf in rats to be approximately twice the cortical BVf. There
is no gold standard method, and the results provided by different
techniques differ significantly. A hypointensity in T2*-weighted
images had already suggested that BVf was higher in the me-
dulla, but the R2*-maps depicted this even more clearly. The
area with apparently very high BVf stretches from the papilla via
the inner medulla to the central outer medulla. We hypothesize
that these phenomena represent the influence of large Fe-rich
vessels (57) located close to the image section, rather than the
actual medullary tissue properties. The dissimilarity between
R2- and R2*-maps in revealing this area of unexpectedly high
BVf further support our hypothesis: unlike R2*, R2 is predom-
inantly sensitive to small vessels and capillaries, because it relies
on water diffusion within the near environment of the vessel
walls, and the surface-to-volume ratio is highest for small vessel
diameters. Hence, R2 would be much less susceptible to the
long-distance effects of a high amount of USPIO within ex-
tremely large blood vessels. Indeed, the locations of apparently
high BVf in the papilla and inner medulla colocalize with the
renal artery and vein, and the interlobar arteries and veins (56).
In the outer medulla, BVf displayed a rather high spatial
heterogeneity and large spatial gradients along the longitudinal
Figure 7. Illustration of blood volume measure-
ment procedure. Shown are parametric maps of
renal R2 and R2* at baseline. Quantitative maps
permit comparisons over time and between ani-
mals, as they are not biased by external factors
such as the RF coil sensitivity (B1) or the location
of the subject with respect to the RF coil. The dif-
ference between R2-/R2*-maps acquired before
and after USPIO is closely related to the local BVf.
For a discussion of the apparent high-BVf area,
stretching from the papilla via the inner medulla to
the central outer medulla, please refer to the Dis-
cussion section.
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(rostral–caudal) axis. Here, large blood vessels (interlobar arter-
ies and veins) surrounding the image section, as well as arcuate
arteries and veins that run along the border between cortex and
medulla (56), may play a role. Owing to the relatively large
section thickness, the T2*-weighted images are considerably sus-
ceptible to magnetic field and frequency dispersions perpendic-
ular to the image plane, created by large USPIO-loaded vessels.
This hinders the assessment of the renal medulla. The choice of
an axial section orientation or much thinner section thickness (if
permitted by the SNR) could help resolve this issue. Despite these
limitations, the variations in cortical BVf during renal VO were
in good agreement with the results obtained from NIRS.
Our approach of parametric mapping of renal T2* and T2
made use of MGE and MSME techniques including respiratory
triggering for respiratory motion compensation. The duration of
each scan was 60–90 s, permitting a TR of 3 min for inter-
leaved T2* and T2 mapping. These protocols are available on
clinical MR scanners, and hence it will be easily translatable to
clinical use. The translation of our approach into the clinic is
fueled by an increasing number of reports that eloquently speak
of the off-label use of ferumoxytol for a broad spectrum of
preclinical and diagnostic imaging applications (32, 43, 44, 58,
59). In the clinical setting, renal T2* and T2 mapping will most
likely be used at time points that are at least hours, if not days or
months, apart. In such a context, a 90-s delay between T2* and T2
scans appears to be short enough. Protocols affording breath-
hold acquisitions could make respiratory triggering unneces-
sary, and parallel imaging capabilities are readily available on
human MR scanners, both permitting acceleration of data
acquisition.
In a laboratory setting, a higher temporal resolution might
be needed to study some acute stimuli applied to animals. Fast
physiological changes demand shorter scan durations and higher
repetition rates. Imaging techniques that provide T2*- and T2-
weighted data (52, 60) provide an alternative to these preclinical
applications. Fast spin-echo variants for T2 and T2* mapping
permit choosing any desired T2*-weighting (including ultrashort
times down to zero) and provide the extra benefit of being
almost immune to image distortion (61, 62). Simultaneous dual-
contrast 2-in-1 rapid acquisition with relaxation enhancement
Figure 8. Maps of renal cortical
and outer medullary T2*, together
with estimated maps of BVf and
oxygen saturation of hemoglobin
(SO2) at baseline, during VO
and the recovery phase. The
maps at baseline and after 10
min of recovery are almost indis-
tinguishable, confirming that the
effects of VO are reversible.
Within-subject repeatability is
demonstrated for renal BVf and
SO2 by comparing the maps de-
rived from 2 different experimen-
tal phases, namely, phase 3 (4
mg of Fe/kg USPIO) and phase
4 (6 mg of Fe/kg USPIO). Test–
retest reliability (repeatability)
was high—the differences be-
tween both iterations are nearly
negligible, even though more
USPIO had been injected in be-
tween them. In addition, SO2
maps were calculated assuming
that renal BVf remains constant
and identical to the baseline con-
dition (bottom row): the missing
compensation for BVf changes
during VO results in SO2 values
being considerably lower than
when BVf was monitored.
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presents a valuable alternative to sequential T2- and T2*-
weighted fast-spin echo acquisitions and promises to eliminate
section-misregistration artifacts induced by bulk or physiolog-
ical motions (63). Further enhancements of the SNR and spatial
resolution could be gained by using cryogenically cooled RF
coils in a preclinical setting (64, 65).
The multiparametric BOLD approach based on combining
the monitoring of T2* and T2 with BVf has not previously been
attempted for renal MR blood oximetry. This study demonstrates
the feasibility of this approach in rats. A high reproducibility of
T2* and T2 mapping and BVf measurements translated into SO2
estimates with similarly high reproducibility.
The impact of the assumptions embedded in the model has
previously been studied and it indicates that the model is suffi-
ciently realistic (66) for the brain. The assumptions about the
microvascular architecture should also hold for the kidney,
except that the BVf used in the numerical study (4%) should be
higher in renal tissue (literature values are contradictory but
typically exceed 10%). However, because the model does not
take into account the effects of renal tubuli, the presented study
results may serve as only an approximate indicator for the
usefulness of such a model-based approach and further inves-
tigation will be needed to advance the model for the kidney.
The current implementation of the model-based analysis
has some methodological constraints that can be improved in
future work. For the current study, intrarenal hematocrit was
assumed to be 0.40, but, in fact, this value is known to vary
throughout the kidney. Strategies to account for this may be
necessary. To account for the susceptibility difference between
blood with and without added ferumoxytol, a literature value of
 for a different USPIO of the same size and at the same
magnetic field strength was used (50). It would be an added
refinement to measure the  for ferumoxytol and include it in
the BVf calculations in the future. Because of our focus on fast,
short-term changes in renal oxygenation, we assumed a con-
stant magnetic field homogeneity, which might change mod-
estly with respect to the kidney owing to respiratory motions
and changes in renal size (renal tissue moves within B0). SO2
results were reported in arbitrary units because B0 effects were
not accounted for in this study. Our initial experiments (Figure 6)
had shown that the effects of magnetic field inhomogeneity on
renal T2* were negligible after local shimming on the kidney,
which we performed routinely. Generally, acquiring B0-maps for
each subject are recommended to permit a B0 correction, if
needed, and exclude a possible bias. Alternatively, acquiring
high-resolution T2* data makes a separate B0 correction unneces-
sary owing to the reduced intravoxel dephasing (49, 67, 68), and it
could represent an attractive way forward, presuming that the scan
time penalty for increasing the spatial resolution is either of no
relevance for the application or can be counteracted by strategies to
accelerate acquisition. This can be accomplished, for example, by
using combined acquisition techniques that integrate a minimum
of 2 imaging strategies for T2* and T2 mapping (69).
Benchmarking BVf and SO2 results against a quantitative
reference is an obvious means of validating experimental results
obtained from a novel MR technique. Currently, a perfect quan-
titative counterpart for MR-derived BVf and SO2 is not avail-
able, as is the case for most MR techniques. Invasive tissue pO2
probes can sample only very small regions, and they measure
tissue pO2 rather than blood oxygenation. NIRS allows measure-
ments of the oxygen saturation of hemoglobin and tissue con-
centration of hemoglobin—a surrogate for BVf—but is currently
limited to probing the cortex due to its low penetration depth.
Comparisons between the occlusion-induced changes in cortical
BVf and SO2 obtained by MRI with the NIRS results for the
cortex yield very good agreement, which should motivate the
Figure 9. Relative changes in
cortical BVf and SO2 derived
from the MR model analysis for
the cortical ROIs (top panel;
n  4), referenced against related
quantitative parameters obtained
with near-infrared spectroscopy
(NIRS; bottom panel; n  6). HbT
 total Hb concentration (per tis-
sue volume). A large increase of
BVf measured with MR during VO
was mirrored by a similarly large
increase in hemoglobin concentra-
tion measured by NIRS, which is
considered a BVf surrogate. Corti-
cal SO2 derived from both meth-
ods decreased markedly during
the short-term venous occlusion
(VO).
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further development of the MR approach proposed here into a
comprehensive renal MR oximetry protocol.
In conclusion, this work established ferumoxytol-based
steady-state MR measurements of renal BVfs for rats at a mag-
netic field strength of 9.4 T. Combining the BVf measurements
with the monitoring of T2* and T2 allowed us to implement
multiparametric quantitative BOLD MRI for the kidney as a
promising approach en route renal blood oximetry. The findings
are encouraging and should stimulate efforts to further improve
this multiparametric technique, with the ultimate aim of trans-
lating it into clinical practice for the evaluation of AKIs and the
development of chronic damage. Accomplishing this goal will
require calibrations through simultaneous quantitative measure-
ments with invasive physiological probes and NIRS in the same
kidney. Once available to the clinicians, multiparametric renal MR
oximetry will represent the first noninvasive method to reliably
measure renal blood oxygenation. It could be combined with
MR techniques for perfusion and diffusion (to probe tubular
volume fraction) en route a comprehensive characterization of
renal hemodynamics and tissue oxygenation, which may be an
important biomarker for the early stages of a range of kidney
diseases.
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